Mantle Cell Lymphoma News and Research

RSS

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field.

1 Jul 2020

Tumor cell–based vaccine may prevent relapse of mantle cell lymphoma

A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment.

22 Jun 2020

New drug can prevent life-threatening anaphylaxis, shows study

For someone with a food or drug allergy, the risk of life-threatening anaphylactic shock lurks around every corner. A new Northwestern Medicine study shows there might be a pill that can be taken proactively to prevent mild to life-threatening anaphylaxis, no matter the cause.

3 Jun 2020

Majority of patients with mantle cell lymphoma may benefit from CAR T-cell therapy KTE-X19

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

1 Apr 2020

Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy

9 Dec 2019

FDA approves Ohio State-developed drug to treat patients with CLL and SCL

On Nov. 21, 2019, the U.S. Food and Drug Administration approved the use of the drug acalabrutinib for first-line therapy in chronic lymphocytic leukemia and small cell lymphoma.

22 Nov 2019

People who have a parent, sibling, or child with blood cancer have higher risk of disease

New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with the disease.

9 Aug 2019

Researchers identify why lymphoma patients may become resistant to specific drug

With more targeted therapies being approved each year for cancer, the development of drug resistance to these agents is a growing concern.

16 May 2019

Small molecule drug may help overcome ibrutinib resistance in mantle cell lymphona

A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma.

9 May 2019

Study gives new insights into how cells leverage GPCRs to control inflammation

G-protein-coupled receptors are everywhere in our bodies. They are embedded in our cell membranes, where they act as signal transducers, allowing cells to respond to their external environments.

19 Sep 2018

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.

28 Aug 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Study reveals HCT as effective treatment for NHL patients regardless of age

Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma showed that survival at 4 years following allogeneic hematopoietic cell transplantation for patients age 65 years and older is comparable to patients age 55 to 64 years.

21 Feb 2018

New modular platform offers robust biological approach that targets endless number of diseases

The biological complexity of cancer and other diseases demands a more formidable arsenal of therapies than currently available. Most therapeutic approaches ignore the dynamic molecular network of genes, targeting instead only very few selected disease-related genes.

1 Feb 2018

FDA grants accelerated approval to new treatment for mantle cell lymphoma

The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.

1 Nov 2017

Penn researchers provide new insights into how Notch drives growth of B-cell cancers

Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States. It is also often mutated in other common B cell tumors, such as mantle cell lymphoma.

23 Oct 2017

UC San Diego researchers receive $18.2 million grant for B cell cancer clinical trial

The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine today unanimously approved an $18.29 million grant to University of California San Diego School of Medicine researchers to fund a phase Ib/IIa clinical trial of a novel combination drug therapy for B-cell cancers.

26 Aug 2017

Research details how lymphoma cells acquire resistance to targeted therapy

Today some patients suffering with mantle cell lymphoma, a type of blood cancer, can be treated with a pill called Ibrutinib, forgoing conventional chemotherapy. However, many are developing a resistance to this treatment.

15 Jun 2017

Cancer drug may help treat food allergies

A cancer drug for patients with certain types of leukemia and lymphoma can also prevent reactions to some of the most common airborne allergies, according to a recent Northwestern Medicine study. The promising data from this pilot study could have greater implications for adults with food allergies.

22 May 2017

$Ibrutinib shows added benefit for refractory mantle cell lymphoma patients$

Ibrutinib shows added benefit for refractory mantle cell lymphoma patients

Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since 2015 also for the treatment of adults with Waldenström macroglobulinaemia. Regarding the treatment of patients with CLL or MCL, the Federal Joint Committee (G-BA) already conducted a benefit assessment and made a decision in 2015.

3 May 2016